US FDA Pauses Biohaven Epilepsy Drug Trial Enrollment
The US FDA has placed a partial clinical hold on Biohaven's experimental epilepsy drug trials following rodent findings. Biohaven shares fell over 15 percent in early trading as the pause affects new patient enrollment.
Xurve View
Insights:
Xurve View
Biohaven paused new patient enrollment in experimental epilepsy drug trials after the United States Food and Drug Administration imposed a partial clinical hold. Shares fell 15% in early trading following the regulatory action.
